Biocon Limited announced that Dr. Sriram AV, Head Quality, Senior Management Personnel, will superannuate on October 31, 2023. Mr. Nitin Tiwari, who has joined the Company shall take-over from Dr. Sriram as Head - Quality with effect from November 01, 2023 and will be part of Senior Management Team. Mr. Nitin Tiwari holds a master's degree in fine
chemicals and drugs from G.S. Institute of Technology & Science, Indore. He has 29 years of rich experience in the pharmaceutical industry, ensuring quality and compliance for a diverse range of dosage forms including oral solids, semi-solids, sterile injectables, vaccines, hormones, oncology, biologics and APIs. Prior to this, he was the Head of Global Quality
Operations at Endo, Ireland, and was responsible for overseeing the Quality function for manufacturing sites in the United States and India. Nitin has also worked with Glenmark Pharmaceutical Limited, Dr. Reddy's Laboratories Limited and Lupin Limited.
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.